Physician profile
Mencia Gomez Devargas
NPI 1285891754
$4,708.84
in general payments reported to CMS, 2019-2025
16 companies · $274 in 2025
The $274 reported for 2025 was more than what a typical Psychosomatic Medicine provider received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $499 · 2020: $79.80 · 2023: $3,594 · 2024: $262 · 2025: $274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,671 · Food and Beverage: $1,460.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,670.71 |
| Food and Beverage | $1,459.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $3,380.98 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $301.34 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $232.22 | 2019-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $177.10 | 2019 | |
| Allergan, INC. | $119.82 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $119.46 | 2023 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $110.78 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $74.83 | 2019-2023 | Trintellix |
| Avanir Pharmaceuticals, INC. | $59.40 | 2019 | |
| Vanda Pharmaceuticals INC. | $27.87 | 2023 | Hetlioz, Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $26.08 | 2025 | Caplyta |
| Alfasigma USA, INC. | $25.22 | 2020 | |
| Alkermes, INC. | $20.19 | 2023 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $19.13 | 2019 | |
| Abbvie INC. | $14.42 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mencia Gomez Devargas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.